<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Commercialization of Novel Assays for COVID-19 Therapeutics

Posted by MD Biosciences on Sep 15, 2020 11:39:11 AM

Our team is excited to announce that we have signed an agreement in partnership with IncellDx, Inc., a global leader in single-cell diagnostics, to evaluate therapeutic biomarkers in COVID-19 and other cytokine storm conditions.

 

With our esoteric immune-based testing, we will validate and offer lab testing in the United States and European Union to measure levels of COVID/cytokine storm-related therapeutics. "Such cytokines are significantly elevated in patients with COVID-19, and usually remain abnormal in recovering patients, but still are suffering from symptoms. These patients are referred to as 'long-haulers' (PR News Centre, 2020)". 

 

To read the full article published by PR News Centre, follow the link below and learn more. 

Learn More

How can MD Biosciences support your clinical programs? Please contact our team with any questions, we are happy to speak with you! 

Email Us

+1 (651) 641-1770

 

Read More

Topics: Inflammation, Biomarkers, Personalized medicine, CLIA, Cytokines, clinical research, clinical diagnostics, COVID-19

Announcing MD Biosciences Bioproducts, LLC in Oakdale, MN

Posted by MD Biosciences on Sep 2, 2020 12:15:08 PM

We are happy to announce that we have established MD Biosciences Bioproducts, LLC. in Oakdale, Minnesota to expand our work and collaborations worldwide. Our team is dedicated to the development, manufacturing and distribution of life science research products suited for inflammatory and autoimmune diseases, neurology, oncology, pain, and metabolism.

View Products

It is our goal to collaborate with pharmaceutical, biotech, academic and government communities to provide you with the tools needed to optimize your research process enabling you to reach your objectives faster. We offer antibodies, reagents and assays for use in various therapeutic areas of research.

 

                                       Please contact us with any questions about our products and capabilities. 

Contact Us

Read More

Topics: news, Research Products, Preclinical Discovery, Life Science, assays, drug development, clinical research, Biotechnology

IHC Staining Image Gallery Now LIVE: High resolution whole slide image samples from in-house histopathology laboratory

Posted by MD Biosciences on Mar 21, 2019 11:57:33 AM

 MD Biosciences has extensive experience in the application of immunohistochemistry to analysis of markers of interest in tissue. Our validated protocols permit such assessments as lymphocyte analysis, cellular proliferation, cellular activation/differentiation, inflammation, biomarker analysis, and much more.

View high-resolution whole slide image examples of our IHC staining results below!

https://www.mdbhistopath.com/immunohistochemistry-image-gallery-ihc-markers 

 

Don't see a marker you're interested in? We provide custom IHC assay development and validation using either commercially available or Sponsor-provided antibodies, and additionally have in-house antibody development facilities for challenging targets. Contact us to discuss a custom project! 

Contact Us Today!  651-641-1770

Read More

Topics: CRO/outsourcing, Biomarkers, Imaging, Pathology, GLP Histopathology, clinical research, Histology, GLP, In-situ Hybridization, Immunohistochemistry, Tissue Processing

Expanding Our Selection of Cutting-Edge CLIA and GLP Capabilities: BD LSR Fortessa™ Flow Cytometer

Posted by MD Biosciences on Jun 22, 2018 11:03:31 AM

MD Biosciences is proud to announce a recent addition to our extensive laboratory services and capabilities: The BD LSR FortessaTM X-20 Flow Cytometer offers the flexibility to support multiparametric (16+ color) analyses with advanced performance and consistency. These capabilities provide increased functionality for applications in preclinical, translational and clinical programs such as immunophenotyping of complex cellular populations, and analysis of cellular activation and proliferation states. Contact us to learn about our flow cytometry capabilities or discuss a study proposal with our scientific team! 

44
Read More

Topics: clinical research, preclinical research, translational research, Biotechnology, immunophenotyping, flow cytometry

MDB Receives 2018 Progress MN Award For Industrial & Economic Development In The Pharma & Biotech Sector Through US Minnesota-Based Site

Posted by MD Biosciences on Apr 6, 2018 11:57:40 AM

Oakdale, Minnesota USA

Nominated via the Minnesota State Dept. Of Employment and Economic Development (DEED), the Progress MN award, offered by Finance & Commerce, recognizes innovative companies that have provided major contributions to business, industrial growth and economic development in innovative and unique ways.

4FrontComplex

MD Biosciences US-site at the 4Front Technology & Office Campus in Oakdale, MN.

 

Taken from Finance and Commerce Website:

https://finance-commerce.com/2018/04/progress-mn-md-biosciences-inc/

 April 6, 2018

 

Eddie Moradian, CEO of the family-owned MD Biosciences Inc., moved to Minnesota in 2008 from Switzerland to take over the company’s American operations.

Headquartered in Switzerland, MD Biosciences operates facilities and laboratories in that country, Israel and Minnesota.

The Minnesota location provides MD Biosciences with a central location and a highly dedicated and educated pool of researchers, health care centers and universities.

The company operates early-stage drug discovery and development laboratories in Minnesota. Labs at the two other locations often participate together in collaborative or fee-for-service pharmaceutical projects, Moradian said.

On a second front, MD Biosciences works closely with pharmaceutical and clinical laboratories in developing advanced clinical diagnostic tools and research products for inflammation, neuro-inflammation, immunological and oncological disease areas.

MD Biosciences has an in-depth expertise and scientific platform that attracts “novel” drug development work in the neurological, inflammatory and oncological disease areas, he said.

Such collaborations, along with internal developments, have resulted in a pipeline of non-opioid compounds for neuropathic pain, an advanced cancer program and blood-based diagnostic tool for a specific cancer, currently in clinical trials.

In 2016, Moradian partnered with Slumberland in the creation of an advanced, multi-technological incubator in Oakdale. “Incubology” offers dry and wet laboratory space, clean rooms and office space to companies in various areas, include biomolecule production, diagnostic processes, medical devices, nanotechnology and chemical synthesis.

“We believe that Incubology will soon grow to be an important regional anchor and seeding ground for new companies and technologies,” he said, “We are truly excited about what the future may bring.”

 

 

About MD Biosciences:

MD Biosciences is a leading provider of preclinical, translational and clinical-phase contract research services.  Established in 1991, MDB provides expertise and services in areas including cancer, cardiovascular, metabolic, inflammatory and neurological conditions including pain-associated disease as well as surgical procedures. Through collaborations with pharmaceutical and medical device pioneers, MDB develops innovative therapeutics and diagnostic assays. Each scientist at MDB is highly specialized, and has an in-depth understanding of a variety of disease mechanisms and how to modulate them. This expertise, strengthened with over 10 years of pharmaceutical efficacy experience, brings value to drug development programs whether the focus is on new therapies or repositioning approved, expiring or failed therapies. Furthermore, MDB's clinical services operate at state of the art laboratories staffed with highly experienced scientists and technicians utilizing the newest and most advanced equipment available. All clinical work is performed according to CLIA standards, and may include assay development and validation, protocol design, sample archiving, and biomarker analysis services.

 

About Incubology:

Incubology was founded to bring technology start-ups together in a shared environment. Members have the benefit of dedicated lab and office space in close proximity to other entrepreneurs from diverse disciplines including biotech, pharma, device, nano and chem. With innovative thinkers from a variety of tech industries in one setting, the opportunity for shared business resources and services is a definite advantage over single-unit space. And as part of a growth-oriented campus, the possibilities for the future are endless.

www.incubology.com

 

About Finance and Commerce:

Finance and Commerce is the only daily newspaper devoted exclusively to business in the Twin Cities (MinneapolisSaint Paul) of Minnesota. Founded in 1887, it provides extensive coverage of Twin Cities business news in the areas of real estate, construction, technology, banking, energy, health care and advertising. It is the official newspaper for Hennepin County and the City of Minneapolis.

https://finance-commerce.com

 

For more information, please contact MD Biosciences at: info-us@mdbiosciences.com 

Read More

Topics: Biomarkers, drug development, clinical research, clinical diagnostics, preclinical research, translational research